Search Results
Apr 26, 2026, 13:00 ET Data at Heart Rhythm 2026 highlight key Boston Scientific therapies
of whether they had a prior ablation (3.9% for both the device and NOACs in patients with prior ablation; 7.5% for the device group vs. 5.7% for the NOAC group in patients with no prior ablation).Long-term outcomes after LAAC therapy in patients not eligible for anticoagulationFive-year
More news about: Boston Scientific Corporation
Dec 19, 2025, 14:35 ET Settlement Reached in Multiple PUCO FirstEnergy Proceedings
Manufacturers' Association Energy Group (OMAEG), Ohio Energy Group (OEG), Northeast Ohio Public Energy Council (NOPEC), Northwest Ohio Aggregation Coalition (NOAC), Ohio Partners for Affordable Energy (OPAE), Citizens Utility Board of Ohio (CUB Ohio), Interstate Gas Supply, LLC (IGS), Retail Energy Supply Association
More news about: FirstEnergy Corp.
Oct 01, 2025, 02:16 ET TAHO Pharma Announces Submission of New Drug Application (NDA) to the U.S. FDA for TAH3311 - The World's First Apixaban Oral Dissolving Film - Represents a Transformational Advancement in Anticoagulant Therapy
treatment and prevention of deep vein thrombosis or pulmonary embolism. With notable safety advantages, it is the leading novel oral anticoagulant (NOAC). About TAHO Pharmaceuticals Ltd. Founded in 2010, TAHO Pharma
More news about: Taho Pharmaceuticals